Lannett announces launch of FDA-approved levothyroxine tablets

They also stated that they had succeeded in separate legal lawsuit situations from Cediprof’s former product distributor. The judges of two courts rejected an application through the ex-spouse of the distribution of a transitional prohibition order prohibiting Cediprof from terminated the previous contract and transferring distribution rights to Lannett.

Lannett said the rulings removed a possible obstacle to begin distributing the product in the United States, despite any ongoing disputes with Cediprof’s former conprojection over the previous completion.

Leave a Comment

Your email address will not be published. Required fields are marked *